Cerevel Therapeutics LLC, the Pfizer Inc. neuroscience spinout launched just over a year ago and backed by private equity giant Bain Capital, has begun late-stage trials of tavapadon, which has shown potential in a variety of treatment settings for Parkinson’s disease.
Cerevel Puts Tavapadon Into Phase III for Parkinson’s
Recruiting 1,200 Patients
The company, launched in October 2018 with neuroscience programs spun out from Pfizer and supported by $350m from Bain, believes it has a treatment that could prove effective across the full spectrum of Parkinson’s disease.
More from Neurological
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.